Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Suresh Senan, Isamu Okamoto, Gyeong won Lee, Yuanbin Chen, Seiji Niho, Gabriel Mak, Wenliang Yao, Norah Shire, Haiyi Jiang, Byoung Chul Cho

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint Dive into the research topics of 'Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study'. Together they form a unique fingerprint.

Medicine & Life Sciences